HL-14 REV. 5/91

DUPONT

1-PP

E. I. DU PONT DE NEMOURS AND COMPANY
Haskell Laboratory for Toxicology
and Industrial Medicine
P.O. Box 50, Elkton Road
New Delaware 19714-0050

DU PONT CENTRAL RESEARCH AND DEVELOPMENT

8EHQ-91-1303
SUPP

November 12, 1992

88910000218 : DCN

EXPRESS MAIL - RETURN RECEIPT REQUESTED

Document Processing Center (TS-790)
Attention: Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street S.W.
Washington, D.C. 20460

8993000P0017

: DCN

Dear Coordinator:

CYMOXANIL

TSCA 8(e) Submission: 8EHQ 0791-1303

This letter is to inform you of results obtained in two in vitro mutagenicity tests conducted with the above referenced material. These tests are an unscheduled DNA synthesis (UDS) assay using cultured rat hepatocytes and a chromosome aberration assay using cultured human lymphocytes.

In the UDS assay, concentrations ranging from 5 to 2000 µg/mL were evaluated. Positive results were induced at concentrations of 500 µg/mL and below; cytotoxicity precluded evaluation of UDS at higher concentrations. In the chromosome aberration assay, concentrations of 100 to 1500 µg/mL were tested, and statistically significant increases in the percent of chromosomally abnormal cells occurred at 1250 and 1500 µg/mL without metabolic activation and at 850, 1000, 1250, and 1500 µg/mL with activation. Cytotoxicity, as measured by a reduction in the mitotic index, was evident at the two highest concentrations under activated and nonactivated conditions.

Under these experimental conditions, this material produced positive results in two in vitro mutagenicity assays. Based on EPA guidance for reporting such data under TSCA Section 8(e), these results appear to be reportable.

Sincerely,

Charles F. Reinhardt

Charles F. Reinhardt, M.D.
Director

Phone: (302)366-5285
CFR/KSB:dj

0 0 0 2

92 NOV 20 AM 8:39